Clee Medical has secured seed funding to advance real-time brain imaging for use in stereotactic neurosurgery.
The financing will support development and clinical validation of the company’s Neuro Access platform, a minimally invasive technology designed to enable real-time visualisation of brain anatomy during surgery.
Founded in October 2024 by Matt Lapinski and Abed Hammoud, the Swiss neurotechnology startup is developing ultra-high-resolution real-time imaging for brain surgery.
Many neurosurgical procedures require navigating delicate brain structures with millimetre-level precision, but anatomical shifts and limited visibility during operations can make accurate targeting difficult.
The Neuro Access platform combines intraoperative optical coherence tomography, a high-resolution imaging method that uses light waves to generate detailed images of tissue, with advanced navigation capabilities to support precision neurosurgery.
It is intended to provide real-time imaging inside the brain to help surgeons access deep brain targets more safely.
Built on years of translational research, the platform is being developed for applications including functional neurosurgery and neuro-oncology.
Clee Medical said the funding will allow it to expand development and clinical programmes, move towards its first-in-human clinical study and accelerate clinical validation of Neuro Access.
The seed round was led by High-Tech Gründerfonds, with participation from Zürcher Kantonalbank, Kickfund, FONGIT and Venture Kick, alongside continued support from existing partner Wyss Geneva.
